Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2...

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Simultaneous p53 inactivation and nuclear factor-κB (NF-κB) hyperactivation are hallmarks of human cancers.
• Current antitumor strategies often target either p53 activation or NF-κB inhibition individually.
• A need exists for agents that can simultaneously modulate both pathways for enhanced therapeutic effect.

Purpose of the Study:

• To provide proof-of-concept for simultaneous targeting of p53-MDM2 interaction and the NF-κB pathway.
• To design and synthesize novel small-molecule inhibitors with dual activity.
• To evaluate the efficacy of these compounds in preclinical cancer models.

Main Methods:

• Rational design and synthesis of pyrrolo[3,4-c]pyrazole derivatives.
• Biochemical assays to assess p53-MDM2 inhibitory activity.
• Analysis of NF-κB pathway components (IκBα phosphorylation, p65 and IKKα/β levels).
• In vivo efficacy studies using a human lung cancer xenograft model (A549).
• Pharmacokinetic evaluation of promising compounds.

Main Results:

• Pyrrolo[3,4-c]pyrazole derivatives demonstrated nanomolar inhibitory activity against the p53-MDM2 interaction.
• Compounds 5q and 5s effectively suppressed NF-κB activation by inhibiting IκBα phosphorylation and altering p65/IKKα/β levels.
• Biochemical assays confirmed direct targeting of the NF-κB pathway by these compounds.
• Compounds 5j, 5q, 5s, and 5u showed significant tumor growth inhibition in the A549 xenograft model.
• Compound 5q exhibited excellent oral bioavailability (72.9%).

Conclusions:

• Pyrrolo[3,4-c]pyrazole derivatives represent a first-in-class small-molecule inhibitor capable of simultaneously targeting p53-MDM2 interaction and the NF-κB pathway.
• These compounds exhibit potent antitumor activity in vitro and in vivo.
• Compound 5q demonstrates favorable pharmacokinetic properties, supporting its potential for further development as an oral anticancer agent.